Cell-based gene therapy against HIV

  title={Cell-based gene therapy against HIV},
  author={Rakesh Dey and Biju Vasudevan Pillai},
  journal={Gene Therapy},
The ability to integrate inside the host genome lays a strong foundation for HIV to play hide and seek with the host’s immune surveillance mechanisms. Present anti-viral therapies, although successful in suppressing the virus to a certain level, fail to wipe it out completely. However, recent approaches in modifying stem cells and enabling them to give rise to potent/resistant T-cells against HIV holds immense hope for eradication of the virus from the host. In this review, we will briefly… 
Pseudotyping of lentiviral vector with novel vesiculovirus envelope glycoproteins derived from Chandipura and Piry viruses.
Both novel envelopes derived from Chandipura and Piry vesiculoviruses were found to be more resistant to inactivation by human serum complement compared to VSV-G and can be harnessed for multiple uses in the future based on the cell type that needs to be gene transduced and possibly for in vivo gene transfer.
Single injection of CD8+ T lymphocytes derived from hematopoietic stem cells - Mathematical and numerical insights
Results indicate that a single, large enough dose of genetically derived CTL may lead to restoration of the cellular immune response and result in long-term control of infection.
Simultaneous Knockout of CXCR4 and CCR5 Genes in CD4+ T Cells via CRISPR/Cas9 Confers Resistance to Both X4- and R5-Tropic Human Immunodeficiency Virus Type 1 Infection.
The results demonstrate the safety and efficacy of CRISPR/Cas9 in multiplex gene modification on peripherally circulating CD4+ T cells, which may promote a functional cure for HIV-1 infection.
Extracellular Matrix-mediated Lung Epithelial Cell Differentiation
The role of the lung ECM is examined in differentiation of pluripotent cells in vitro and the robust inductive capacity of the native matrix alone is demonstrated using decellularized adult lung scaffolds.


Stem cell-based anti-HIV gene therapy.
Two major approaches that are currently underway in the development of stem cell-based gene therapy to target HIV are discussed: one that focuses on the protection of cells from productive infection with HIV, and the other that focuseson targeting immune cells to directly combat HIV infection.
Genetic therapies against HIV
Gene therapy offers the promise of preventing progressive HIV infection by sustained interference with viral replication in the absence of chronic chemotherapy, andGene-targeting strategies are being developed with RNA-based agents, and protein-basedagents, such as the mutant HIV Rev protein M10, fusion inhibitors and zinc-finger nucleases.
Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus
The potential of the CRISPR/Cas9 system to edit the HIV-1 genome and block its expression is shown and this system was also able to remove internal viral genes from the host cell chromosome.
Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates
These studies provide a successful demonstration that siRNAs can be used together with hematopoietic stem cell transplant to stably modulate gene expression in primates and potentially treat blood diseases such as HIV-1.
In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells
The presence of genetically modified HIV-specific CTL can form a functional antiviral response in vivo, indicating that stem cell based gene therapy may be a feasible approach in the treatment of chronic viral infections and providing a foundation towards the development of this type of strategy.
Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.
It is concluded that gene-modified T cells have the potential to decrease the fitness of HIV-1 and conditionally replicative lentiviral vectors have a promising safety profile in T cells.
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA
The CRISPR/Cas9 complex efficiently mutates and deactivates HIV-1 proviral DNA in latently infected Jurkat cells and revealed a highly efficient Cas9 target site within the second exon of Rev that represents a promising target to be further explored in the CRISpr/ Cas9-based cure strategy.
Antibody-based Protection Against HIV Infection by Vectored ImmunoProphylaxis
It is shown that humanized mice receiving VIP appear to be fully protected from HIV infection, even when challenged intravenously with very high doses of replication-competent virus, suggesting that successful translation of this approach to humans may produce effective prophylaxis against HIV.
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation.
To the Editor: Infection with the human immunodeficiency virus (HIV) requires entry into target cells by binding of the viral envelope to the CD4 receptor and to either the chemokine (C-C motif)
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation.
Successful reconstitution of CD4(+) T cells at the systemic level as well as in the gut mucosal immune system after CCR5Δ32/Δ 32 stem cell transplantation is demonstrated, suggesting that cure of HIV has been achieved in this patient.